NPC’s Dr. Dubois to Discuss Value Frameworks & Risk-Sharing at Pharmaceutical Summit

National Pharmaceutical Council (NPC) Chief Science Officer Robert W. Dubois, MD, PhD, will present “Developing and Using Value-Based Frameworks for Pharmaceuticals and Guiding Standards for How to Implement Such Frameworks Correctly,” on Wednesday, June 8, at 1:30 pm ET, and participate in a following panel discussion, “Value-Based Risk Sharing: Views from the Trenches,” at 2:00 pm ET during the Pharmaceutical Summit on Business & Compliance Issues in Managed Markets.

In his first presentation about value frameworks, Dr. Dubois will speak about the recent proliferation of value frameworks. He’ll reference NPC’s Guiding Practices for Patient-Centered Value Assessment that identify key aspects of value assessments and address where improvements are needed in existing frameworks. Dr. Dubois also will discuss why there should not be a single nationally determined assessment of value, and explain why budget impact analyses should be considered separately from value assessments.

During his panel presentation, Dr. Dubois will explore how risk-sharing agreements have the potential to create win-win opportunities for the biopharmaceutical industry and payers, and address challenges that can hinder the success of these agreements.

He will be joined by two panelists who have experience with risk-sharing agreements: Edmund J. Pezalla, MD, MPH, national medical director, pharmacy policy and strategy, Aetna, and Robert Spurr, MBA, vice president and country head, patient access and health policy, Novartis Pharmaceuticals.

They’ll discuss the factors that led them to develop risk-sharing agreements, keys to successful agreements, and considerations for other organizations interested in these arrangements.

Register now to attend the conference, which will take place at the Grand Hyatt in Washington, DC.